What is Wedbush's price target for ALBO?

Wedbush's latest stated price target for Albireo Pharma Inc. (ALBO) is $42, from its action on Jan 9, 2023.

What is Wedbush's rating on ALBO?

Wedbush rates ALBO Neutral, a neutral rating, as of Jan 9, 2023.

When did Wedbush last change its view on ALBO?

On Jan 9, 2023, Wedbush downgrades to Neutral from Outperform, price target $53 to $42.

Wedbush ALBO price target and rating history

Albireo Pharma Inc. (ALBO) · Health Care

Wedbush rates Albireo Pharma Inc. (ALBO) Neutral with a $42 price target, as of its latest action on Jan 9, 2023. It has published 4 rating actions on ALBO since July 2021, including 0 upgrades and 1 downgrade.

Current rating: Neutral
Price target: $42
Median target, all firms: Too few
Actions on ALBO: 4

Wedbush price target on ALBO

Wedbush price target on ALBO, each point a stated target, July 2021 to January 2023.

Every Wedbush rating on ALBO

Jan 9, 2023
DowngradeWedbush downgrades to Neutral from Outperform, price target $53 to $42
Mar 28, 2022
InitiateWedbush starts coverage at Outperform, price target $75
Sep 16, 2021
ReiterateWedbush raises its price target to $84 from $82, keeps Outperform
Jul 21, 2021
ReiterateWedbush raises its price target to $82 from $73, keeps Outperform

Questions about Wedbush and ALBO

What is Wedbush's price target for ALBO?: Wedbush's latest stated price target for Albireo Pharma Inc. (ALBO) is $42, from its action on Jan 9, 2023.
What is Wedbush's rating on ALBO?: Wedbush rates ALBO Neutral, a neutral rating, as of Jan 9, 2023.
When did Wedbush last change its view on ALBO?: On Jan 9, 2023, Wedbush downgrades to Neutral from Outperform, price target $53 to $42.

All Wedbush ratings ALBO news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.